CSBIO(SZ:300255)2026-01-29 08:40Financial Projections - The company expects a net profit in the range of -28,500 to -19,000 thousand CNY for 2025, representing a year-on-year decline of 14.24% to 23.84%[4] - The net profit after deducting non-recurring gains and losses is projected to be between -28,600 and -19,100 thousand CNY, with a slight increase of 0.12% to 33.30% compared to the previous year[4] - The financial data in the earnings forecast is preliminary and has not been audited by the accounting firm, with final figures to be disclosed in the 2025 annual report[8] Market Conditions - The main reason for the loss is the intensified competition in the heparin drug industry, leading to a decline in revenue from core heparin products and low gross margins due to centralized procurement and raw material price fluctuations[6] Sales and Expenses - Sales expenses are expected to decrease significantly in 2025 due to adjustments in sales strategies and optimization of sales team configurations following the implementation of centralized procurement policies[7] - The company has made provisions for credit and asset impairment based on preliminary assessments of the recoverability of accounts receivable and other receivables[7]